What is the mechanism of ajovy?

Ajovy (fremanezumab) works by blocking calcitonin gene-related peptide (CGRP), a signaling protein involved in migraine attacks.

How does blocking CGRP stop migraine?

CGRP plays a role in migraine by promoting pain signaling and blood vessel/nerve-related changes in the trigeminal system. Ajovy is a monoclonal antibody designed to bind CGRP so it can’t activate its receptors, which reduces downstream migraine signaling associated with attack development.[1]

Is Ajovy preventive or used to treat attacks once they start?

Ajovy is used to prevent migraine. Because it targets the CGRP pathway involved in migraine biology, it’s given on a preventive schedule rather than as an acute treatment during an ongoing attack.[1]

What kind of drug is Ajovy?

Ajovy is a fully human monoclonal antibody. That matters because it doesn’t work like small-molecule drugs that inhibit enzymes or receptors directly; instead, it specifically binds its target (CGRP) in the body.[1]

Are there other CGRP-targeting options?

Ajovy is part of the CGRP-targeted migraine drug class (with other monoclonal antibodies that either target CGRP itself or the CGRP receptor). The key difference is which point in the CGRP pathway the antibody blocks.[1]

Sources
[1] https://www.drugs.com/monograph/ajovy.html